Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research 2018, 6: 1039-1045. PMID: 30002157, PMCID: PMC6230261, DOI: 10.1158/2326-6066.cir-18-0067.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesCheckpoint blockade immunotherapyMBM patientsOverall survivalBlockade immunotherapyStage 4 melanomaNational Cancer DatabaseManagement of patientsKaplan-Meier techniqueLarge national cohortEarly clinical trialsBrain metastasesExtracranial metastasesSurvival benefitAdvanced melanomaOS improvementNational cohortCancer DatabaseClinical trialsNovel therapiesU.S. cancerPatientsTherapy trialsProportional hazardsFDA approval